| 发明名称 |
BIOMARKER |
| 摘要 |
The invention is directed, in part, to selective cancer treatment regimes based on assaying for the presence or absence of a mutation in a nucleic acid that encodes MLL1 or for the presence of reduced levels of MLL1. |
| 申请公布号 |
US2016031836(A1) |
申请公布日期 |
2016.02.04 |
| 申请号 |
US201414774511 |
申请日期 |
2014.03.14 |
| 申请人 |
zhou Wenlai;CHEN Jinyun;WILSON Christopher;CHEN Yaoyu |
发明人 |
Chen Jinyun;CHEN Yaoyu;WILSON Christopher;ZHOU Wenlai |
| 分类号 |
C07D261/18;C12Q1/68 |
主分类号 |
C07D261/18 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of selectively treating a subject having cancer, including selectively administering a therapeutically effective amount of (5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, or a pharmaceutically acceptable salt thereof, to the subject on the basis of the subject having reduced levels of MLL1 |
| 地址 |
US |
